Saturday, 31 October 2026European Markets

RANDSTAD NV And SYNERGIE Have A High Dividend Yield And Return On Equity In The Staffing & Employment Services Industry.

Loading stream...

(vianews) - randstad nv (rand.as) is among this list of stock assets with the highest dividend rate and return on equity on the staffing & employment services industry.

financial asset price forward dividend yield return on equity
randstad nv (rand.as) €51.10 4.99% 16.01%
synergie (sdg.pa) €33.80 2.36% 14.82%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. randstad nv (rand.as)

4.99% forward dividend yield and 16.01% return on equity

randstad n.v. provides solutions in the field of work and human resources (hr) services. it offers temporary staffing and permanent placement services for the light industrial, office and administrative, manufacturing and logistics, and other specialty areas, as well as payroll services. the company also offers on-site solutions for managing a client's workforce with specific skill sets and a fluctuating level of demand for the fast-moving consumer goods, automotive, life sciences, contact centers, manufacturing, and logistics, as well as the administrative and professional segments. in addition, it recruits experienced staff for managerial and professional roles in a range of sectors and disciplines, including it, engineering, finance, healthcare, hr, education, legal affairs, sales and marketing and communications. further, the company provides managed services programs, recruitment process outsourcing, outplacement and career development, and online talent acquisition. it has operations in north america, france, the netherlands, germany, belgium, luxembourg, italy, iberia, other european countries, and internationally. the company was formerly known as randstad holding nv and changed its name to randstad n.v. in april 2018. randstad n.v. was founded in 1960 and is headquartered in diemen, the netherlands.

earnings per share

as for profitability, randstad nv has a trailing twelve months eps of €4.07.

pe ratio

randstad nv has a trailing twelve months price to earnings ratio of 12.56. meaning, the purchaser of the share is investing €12.56 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.01%.

more news about randstad nv.

2. synergie (sdg.pa)

2.36% forward dividend yield and 14.82% return on equity

synergie se provides human resources management and development services for companies and institutions in france, belgium, other northern and eastern europe, italy, spain, portugal, canada, and australia. it offers temporary work, recruitment, out-placement, social engineering, consultancy, and training services. the company serves various specialized sectors and industries, such as renewable energy, transport and logistics, construction and public works, healthcare, agri-food, and tertiary sectors. synergie se was founded in 1969 and is headquartered in paris, france.

earnings per share

as for profitability, synergie has a trailing twelve months eps of €3.51.

pe ratio

synergie has a trailing twelve months price to earnings ratio of 9.63. meaning, the purchaser of the share is investing €9.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.82%.

yearly top and bottom value

synergie's stock is valued at €33.80 at 16:40 est, under its 52-week high of €35.25 and way higher than its 52-week low of €28.50.

more news about synergie.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com